Page last updated: 2024-10-24

carbazilquinone and Acute Myelogenous Leukemia

carbazilquinone has been researched along with Acute Myelogenous Leukemia in 2 studies

Carbazilquinone: An alkylating agent structurally similar to MITOMYCIN and found to be effective in the treatment of leukemia and various other neoplasms in mice. It causes leukemia and thrombocytopenia in almost all human patients.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Higuchi, T1
Okada, S1
Mori, H1
Niikura, H1
Omine, M1
Terada, H1
Tabata, M1
Imagawa, S1
Tarumoto, T1
Ohmine, K1
Hatake, K1
Miura, Y1
Ozawa, K1

Other Studies

2 other studies available for carbazilquinone and Acute Myelogenous Leukemia

ArticleYear
Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent.
    Cancer, 1995, Jan-15, Volume: 75, Issue:2

    Topics: Adult; Aged; Carbazilquinone; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Leukemia, M

1995
Essential thrombocythemia transformed to acute myelogenous leukemia with t(3;17)(p24; q12), del(5)(q13q34) after treatment with carboquone and hydroxyurea.
    Japanese journal of clinical oncology, 2000, Volume: 30, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Carbazilquinone; Chromosomes, Human, P

2000